Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy
ABSTRACT Background The safety of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)‐rich hemp oil supplementation in dogs with cancer receiving chemotherapy has not been investigated. Objectives To evaluate the safety, tolerability, and influence on doxorubicin exposure over time of oral CBD/CBDA...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Journal of Veterinary Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jvim.70179 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850076065933819904 |
|---|---|
| author | Amandine Lejeune Sandra Bechtel Rowan Milner Lana Fagman Francisco A. Leal Yepes Joseph J. Wakshlag |
| author_facet | Amandine Lejeune Sandra Bechtel Rowan Milner Lana Fagman Francisco A. Leal Yepes Joseph J. Wakshlag |
| author_sort | Amandine Lejeune |
| collection | DOAJ |
| description | ABSTRACT Background The safety of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)‐rich hemp oil supplementation in dogs with cancer receiving chemotherapy has not been investigated. Objectives To evaluate the safety, tolerability, and influence on doxorubicin exposure over time of oral CBD/CBDA‐rich hemp oil supplementation in dogs diagnosed with high grade lymphoma undergoing CHOP chemotherapy. Animals Client‐owned dogs diagnosed with lymphoma. Methods Dogs were enrolled in this prospective, double‐blinded, randomized, placebo‐controlled clinical trial to receive either CBD/CBDA‐rich hemp oil capsules or placebo during one cycle of CHOP chemotherapy. Primary outcomes evaluated included adverse events during chemotherapy, quality of life scores and doxorubicin area under the curve (AUC) over a 5‐week period. Results Twenty‐five dogs were enrolled, with 19 completing the trial. CBD/CBDA supplementation did not significantly affect doxorubicin AUC in the intervention group. The doxorubicin AUC was not different between groups at week 0 [placebo 390.8 nM/h (318.6–479.4); CBD/CBDA 403.4 nM/h (351.9–462.5)] but was different at week 5 [placebo 572.6 (448.3–731.2); CBD/CBDA 406.8 (3.23.2–551.8)]. CBD/CBDA supplementation was well‐tolerated, and no serious adverse events were observed. No significant differences between groups were observed in hematological and biochemical variables. The mean (range) quality of life scores for placebo and CBD were 7.56 (0, 35), and 10.75 (0, 56), respectively, with no significant differences. Conclusion and Clinical Importance Short‐term oral CBD/CBDA‐rich hemp supplementation appeared safe and well‐tolerated in dogs undergoing CHOP chemotherapy for lymphoma. |
| format | Article |
| id | doaj-art-ab0d812f556b483a8be15affc24655b7 |
| institution | DOAJ |
| issn | 0891-6640 1939-1676 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Veterinary Internal Medicine |
| spelling | doaj-art-ab0d812f556b483a8be15affc24655b72025-08-20T02:46:07ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762025-07-01394n/an/a10.1111/jvim.70179Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP ChemotherapyAmandine Lejeune0Sandra Bechtel1Rowan Milner2Lana Fagman3Francisco A. Leal Yepes4Joseph J. Wakshlag5Department of Surgical and Radiological Sciences University of California, School of Veterinary Medicine Davis California USADepartment of Small Animal Clinical Sciences University of Florida, College of Veterinary Medicine Gainesville Florida USADepartment of Small Animal Clinical Sciences University of Florida, College of Veterinary Medicine Gainesville Florida USADepartment of Small Animal Clinical Sciences University of Florida, College of Veterinary Medicine Gainesville Florida USADepartment of Population Medicine and Diagnostic Sciences Cornell University College of Veterinary Medicine Ithaca New York USADepartment of Clinical Sciences Cornell University College of Veterinary Medicine Ithaca New York USAABSTRACT Background The safety of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)‐rich hemp oil supplementation in dogs with cancer receiving chemotherapy has not been investigated. Objectives To evaluate the safety, tolerability, and influence on doxorubicin exposure over time of oral CBD/CBDA‐rich hemp oil supplementation in dogs diagnosed with high grade lymphoma undergoing CHOP chemotherapy. Animals Client‐owned dogs diagnosed with lymphoma. Methods Dogs were enrolled in this prospective, double‐blinded, randomized, placebo‐controlled clinical trial to receive either CBD/CBDA‐rich hemp oil capsules or placebo during one cycle of CHOP chemotherapy. Primary outcomes evaluated included adverse events during chemotherapy, quality of life scores and doxorubicin area under the curve (AUC) over a 5‐week period. Results Twenty‐five dogs were enrolled, with 19 completing the trial. CBD/CBDA supplementation did not significantly affect doxorubicin AUC in the intervention group. The doxorubicin AUC was not different between groups at week 0 [placebo 390.8 nM/h (318.6–479.4); CBD/CBDA 403.4 nM/h (351.9–462.5)] but was different at week 5 [placebo 572.6 (448.3–731.2); CBD/CBDA 406.8 (3.23.2–551.8)]. CBD/CBDA supplementation was well‐tolerated, and no serious adverse events were observed. No significant differences between groups were observed in hematological and biochemical variables. The mean (range) quality of life scores for placebo and CBD were 7.56 (0, 35), and 10.75 (0, 56), respectively, with no significant differences. Conclusion and Clinical Importance Short‐term oral CBD/CBDA‐rich hemp supplementation appeared safe and well‐tolerated in dogs undergoing CHOP chemotherapy for lymphoma.https://doi.org/10.1111/jvim.70179cancercaninecannabisnon‐hodgkin lymphomapharmacokinetics |
| spellingShingle | Amandine Lejeune Sandra Bechtel Rowan Milner Lana Fagman Francisco A. Leal Yepes Joseph J. Wakshlag Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy Journal of Veterinary Internal Medicine cancer canine cannabis non‐hodgkin lymphoma pharmacokinetics |
| title | Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy |
| title_full | Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy |
| title_fullStr | Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy |
| title_full_unstemmed | Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy |
| title_short | Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy |
| title_sort | safety efficacy and doxorubicin pharmacokinetics during cannabidiol cannabidiolic acid rich hemp oil use in dogs with lymphoma undergoing chop chemotherapy |
| topic | cancer canine cannabis non‐hodgkin lymphoma pharmacokinetics |
| url | https://doi.org/10.1111/jvim.70179 |
| work_keys_str_mv | AT amandinelejeune safetyefficacyanddoxorubicinpharmacokineticsduringcannabidiolcannabidiolicacidrichhempoiluseindogswithlymphomaundergoingchopchemotherapy AT sandrabechtel safetyefficacyanddoxorubicinpharmacokineticsduringcannabidiolcannabidiolicacidrichhempoiluseindogswithlymphomaundergoingchopchemotherapy AT rowanmilner safetyefficacyanddoxorubicinpharmacokineticsduringcannabidiolcannabidiolicacidrichhempoiluseindogswithlymphomaundergoingchopchemotherapy AT lanafagman safetyefficacyanddoxorubicinpharmacokineticsduringcannabidiolcannabidiolicacidrichhempoiluseindogswithlymphomaundergoingchopchemotherapy AT franciscoalealyepes safetyefficacyanddoxorubicinpharmacokineticsduringcannabidiolcannabidiolicacidrichhempoiluseindogswithlymphomaundergoingchopchemotherapy AT josephjwakshlag safetyefficacyanddoxorubicinpharmacokineticsduringcannabidiolcannabidiolicacidrichhempoiluseindogswithlymphomaundergoingchopchemotherapy |